TRANSCODE THERAPEUTICS, INC.: net property, plant and equipment
Net property, plant and equipment for TRANSCODE THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All TRANSCODE THERAPEUTICS, INC. financial histories
What this measure means
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
Exact concept: us-gaap:PropertyPlantAndEquipmentNet. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2021-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 370,681 | USD | 2026-04-15 | 10-K · 0001104659-26-043810 |
| At date | 2024-12-31 | 51,574 | USD | 2026-04-15 | 10-K · 0001104659-26-043810 |
| At date | 2023-12-31 | 120,707 | USD | 2025-04-15 | 10-K · 0001558370-25-004843 |
| At date | 2022-12-31 | 208,581 | USD | 2024-04-01 | 10-K · 0001410578-24-000413 |
| At date | 2021-12-31 | 206,268 | USD | 2023-03-31 | 10-K · 0001104659-23-040158 |
Related financial histories
- TRANSCODE THERAPEUTICS, INC.: total assets
- TRANSCODE THERAPEUTICS, INC.: total liabilities
- TRANSCODE THERAPEUTICS, INC.: stockholders equity
- TRANSCODE THERAPEUTICS, INC.: cash and cash equivalents
- TRANSCODE THERAPEUTICS, INC.: net income or loss
- TRANSCODE THERAPEUTICS, INC.: operating cash flow
- TRANSCODE THERAPEUTICS, INC.: capital expenditure payments
- TRANSCODE THERAPEUTICS, INC.: financing cash flow
- TRANSCODE THERAPEUTICS, INC.: investing cash flow
- TRANSCODE THERAPEUTICS, INC.: retained earnings or deficit
- TRANSCODE THERAPEUTICS, INC.: basic weighted-average shares
- TRANSCODE THERAPEUTICS, INC.: diluted weighted-average shares
- TRANSCODE THERAPEUTICS, INC.: basic earnings per share
- TRANSCODE THERAPEUTICS, INC.: diluted earnings per share
- TRANSCODE THERAPEUTICS, INC.: income tax expense or benefit
- TRANSCODE THERAPEUTICS, INC.: share-based compensation expense
- TRANSCODE THERAPEUTICS, INC.: operating income or loss
- TRANSCODE THERAPEUTICS, INC.: current assets
- TRANSCODE THERAPEUTICS, INC.: interest expense
- TRANSCODE THERAPEUTICS, INC.: current liabilities
- TRANSCODE THERAPEUTICS, INC.: operating expenses
- TRANSCODE THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- TRANSCODE THERAPEUTICS, INC. / CIK 0001829635
- Captured
- 2026-09-21T17:29:25.770Z
- SEC response SHA-256
9f045b8c6b6066ebea672fd5e78fdf7e2d4af73b1e7786053a28677ad0402dc5
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001829635.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))